EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B



Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B



Journal of Clinical Oncology 11(8): 1559-1565



Purpose: The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II multicenter trial to evaluate the activity of two cisplatin-containing regimens (cisplatin and mitomycin (CM), or cisplatin and doxorubicin (CD)) in patients with malignant pleural or peritoneal mesothelioma (protocol CALGB 8435). Patients and Methods: Seventy-nine patients were entered between June 1984 and October 1986. Eligibility included a performance status of 0 to 2 by CALGB criteria, and no prior chemotherapy. Central pathology review was performed. Randomization was stratified according to the cell type (epithelial v mixed or sarcomatous) and the presence of measurable versus assessable disease. Of the 79 patients entered, 70 were included in this analysis (35 on CM and 35 on CD), including 48 with epithelial cell type and 22 with mixed or sarcomatous cell types. Sixty-six patients had pleural mesothelioma and four had peritoneal mesothelioma. There were 34 cases with measurable disease and 36 with assessable disease. Results: The overall response rate was 26% for CM (two complete responses (CRs), three partial responses (PRs), and four regressions) and 14% for CD (four PRs and one regression). Median time to treatment failure was 3.6 months for CM and 4.8 months for CD, and median survival duration from study entry was 7.7 and 8.8 months, respectively, with no significant differences between treatments. Good performance status (0 or 1) was associated with significantly longer survival duration (P = .013). Both regimens were well tolerated and there were no treatment-related deaths due to toxicity. Conclusion: Moderate antitumor activity has been observed with both regimens. In this randomized phase II trial, the overall response rates, time to treatment failure, and overall survival appear to be similar for the two regimens tested.

(PDF emailed within 0-6 h: $19.90)

Accession: 009295891

Download citation: RISBibTeXText

PMID: 8336195

DOI: 10.1200/jco.1993.11.8.1559



Related references

Affective styles in mood and anxiety disorders - Clinical validation of the "Affective Style Questionnaire" (ASQ). Journal of Affective Disorders 238: 392-398, 2018

Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer ChemoTherapy and Pharmacology 68(1): 37-43, 2011

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma A Phase II multicenter trial of the Italian Group on Rare Tumors and the Italian Lung Cancer Task Force. Cancer 92(3): 650-656, August 1, 2001

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: A phase II FONICAP trial. Cancer 79(10): 1897-1902, 1997

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. Cancer 77(2): 245-250, 1996

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 92(3): 650-656, 2001

Randomized phase iii trial of doxorubicin plus cyclophosphamide plus bcg vs doxorubicin plus cisplatin vs doxorubicin plus cisplatin plus bcg in stages iii and iv ovarian cancer. Proceedings American Society of Clinical Oncology Annual Meeting 5: 119, 1986

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer 34(2): 289-295, 2001

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the cancer and leukemia group B. Cancer 82(8): 1578-1584, 1998

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Annals of Oncology 17(7): 1111-1119, 2006

Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Annals of Oncology 12(7): 967-974, 2001

Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 48(3): 423-428, 2005

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31(2-3): 311-317, 2001

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 44(2): 251-259, 2004